Andrew Weickhardt
Scientist
John M. Mariadason Lab Ludwig Center at Melbourne
Ludwig Institute for Cancer Research
Australia
Biography
My main areas of responsibility involve management of patients with genitourinary cancer and involvement in clinical trials in this patient population. I also work in drug development/phase I clinical trials. My translational cancer research interests involve the optimization of precision medicine. This involves the identification of novel targets, refinement of biomarker assays, monitoring and evaluation of therapeutic response to targeted therapy, and identification of resistance mechanisms to targeted therapy. An example of this is my work exploring potentially highly targetable gene fusions in cancers such as colon and prostate cancer.
Research Interest
Genitourinary cancer, clinical trials, drug development, biomarker assays
Publications
-
Price, Timothy J., et al. "Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer." Journal of Clinical Oncology 29.19 (2011): 2675-2682.
-
Weickhardt, Andrew J., et al. "Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer." Journal of Thoracic Oncology 7.12 (2012): 1807-1814.
-
Doebele, Robert C., et al. "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non–small cell lung cancer." Clinical cancer research 18.5 (2012): 1472-1482.
